This Article Full Text (OnlineFirst PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sucker, C. Articles by Zotz, R. B. Search for Related Content PubMed PubMed Citation Articles by Sucker, C. Articles by Zotz, R. B. Social Bookmarking                   What's this?

Use of Recombinant Factor VIIa in Inherited and Acquired von Willebrand Disease

^* To whom correspondence should be addressed. E-mail: zotz{at}med.uni-duesseldorf.de.

	Abstract

Recombinant factor VIIa (rFVIIa) is increasingly used outside the labeled indications for the treatment of life-threatening bleeding episodes after failure of respective standard therapy. In this article, the authors focus on the use of the agent in patients with inherited or acquired von Willebrand disease (vWD). Although the current experience is sparse, published cases indicate the high efficacy of rFVIIa for the treatment of patients refractory to conventional treatment. The agent may be used in patients with congenital vWD complicated by alloantibodies directed against substituted von Willebrand factor or in the presence of concomitant hemostatic defects as well as acquired vWD with hitherto limited therapeutic options. Controlled clinical studies are necessary to define the use of rFVIIa in this clinical setting.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?